Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Blood Adv ; 8(9): 2085-2093, 2024 May 14.
Article in English | MEDLINE | ID: mdl-38315043

ABSTRACT

ABSTRACT: Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential to cause new or worsening hypertension (HTN). Little is known about the optimal treatment of BTKi-associated HTN. Randomly selected patients with lymphoid malignancies on a BTKi and antihypertensive drug(s) and with at least 3 months of follow-up data were sorted into 2 groups: those diagnosed with HTN before BTKi initiation (prior-HTN), and those diagnosed with HTN after BTKi initiation (de novo HTN). Generalized estimating equations assessed associations between time varying mean arterial pressures (MAPs) and individual anti-HTN drug categories. Of 196 patients included in the study, 118 had prior-HTN, and 78 developed de novo HTN. Statistically significant mean MAP reductions were observed in patients with prior-HTN who took ß blockers (BBs) with hydrochlorothiazide (HCTZ), (-5.05 mmHg; 95% confidence interval [CI], 10.0 to -0.0596; P = .047), and patients diagnosed with de novo HTN who took either an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) with HCTZ (-5.47 mmHg; 95% CI, 10.9 to -0.001; P = .05). These regimens also correlated with the greatest percentages of normotensive MAPs. Treatment of HTN in patients taking a BTKi is challenging and may require multiple antihypertensives. Patients with prior-HTN appear to benefit from combination regimens with BBs and HCTZ, whereas patients with de novo HTN appear to benefit from ACEi/ARBs with HCTZ. These results should be confirmed in prospective studies.


Subject(s)
Adenine , Antihypertensive Agents , Hypertension , Piperidines , Humans , Adenine/analogs & derivatives , Adenine/therapeutic use , Adenine/adverse effects , Piperidines/therapeutic use , Hypertension/drug therapy , Hypertension/chemically induced , Male , Female , Retrospective Studies , Middle Aged , Aged , Antihypertensive Agents/therapeutic use , Antihypertensive Agents/adverse effects , Protein Kinase Inhibitors/therapeutic use , Protein Kinase Inhibitors/adverse effects , Pyrimidines/therapeutic use , Pyrimidines/adverse effects , Pyrazoles/therapeutic use , Pyrazoles/adverse effects , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors
2.
Eur J Haematol ; 108(5): 379-382, 2022 May.
Article in English | MEDLINE | ID: mdl-35043475

ABSTRACT

INTRODUCTION: Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations. At the time of relapse, although treatment guidelines recommend re-treatment with a PNA alone or in combination with rituximab (R), practice patterns vary and data supporting each approach are limited. METHODS: We conducted a multisite outcomes analysis of patients treated for HCL between 1995 and 2018 at six US medical centers. All patients were treated with frontline PNA and subsequently required treatment with a PNA alone (PNA) or with R (+R). RESULTS: Of the 88 patients analyzed, 56 (63.6%) received second-line PNA and 22 (36.4%) received a PNA + R. Baseline characteristics of both groups were similar. There was no difference in median PFS [67 months (95% CI 43.8 non-reached (NR)) vs. 65 months (95% CI 60-NR)] or 5-year OS [98% (95% CI 0.94-1) vs. 94% (95% CI 0.83-1), p = .104] in the PNA versus PNA + R cohorts, respectively. CONCLUSION: To our knowledge, this is the largest study evaluating the role of R in treatment of relapsed HCL and suggests that there is no advantage to the addition of R to PNA therapy at the time of first re-treatment.


Subject(s)
Leukemia, Hairy Cell , Nucleosides , Humans , Leukemia, Hairy Cell/drug therapy , Purine Nucleosides , Purines , Recurrence , Rituximab/therapeutic use , Treatment Outcome
3.
Clin Cancer Res ; 26(14): 3589-3596, 2020 07 15.
Article in English | MEDLINE | ID: mdl-32198151

ABSTRACT

PURPOSE: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. EXPERIMENTAL DESIGN: To address this, we conducted a large international study to identify a cohort of 326 patients who discontinued venetoclax and have been subsequently treated. Coprimary endpoints were overall response rate (ORR) and progression-free survival for the post-venetoclax treatments stratified by treatment type [Bruton's tyrosine kinase inhibitor (BTKi), PI3K inhibitor (PI3Ki), and cellular therapies]. RESULTS: We identified patients with CLL who discontinued venetoclax in the first-line (4%) and relapsed/refractory settings (96%). Patients received a median of three therapies prior to venetoclax; 40% were BTKi naïve (n = 130), and 81% were idelalisib naïve (n = 263). ORR to BTKi was 84% (n = 44) in BTKi-naïve patients versus 54% (n = 30) in BTKi-exposed patients. We demonstrate therapy selection following venetoclax requires prior novel agent exposure consideration and discontinuation reasons. CONCLUSIONS: For BTKi-naïve patients, selection of covalently binding BTKis results in high ORR and durable remissions. For BTKi-exposed patients, covalent BTK inhibition is not effective in the setting of BTKi resistance. PI3Kis following venetoclax do not appear to result in durable remissions. We conclude that BTKi in naïve or previously responsive patients and cellular therapies following venetoclax may be the most effective strategies.See related commentary by Rogers, p. 3501.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell , Bridged Bicyclo Compounds, Heterocyclic , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Phosphatidylinositol 3-Kinases , Protein Kinase Inhibitors/adverse effects , Pyrazoles , Pyrimidines , Sulfonamides
4.
Biol Blood Marrow Transplant ; 25(12): 2383-2387, 2019 12.
Article in English | MEDLINE | ID: mdl-31394277

ABSTRACT

Standard therapy for relapsed or refractory (rel/ref) primary mediastinal large B cell lymphoma (PMBCL) is salvage therapy followed by autologous (auto) hematopoietic stem cell transplantation (HSCT). However, many patients have refractory disease and are unable to undergo autoHSCT, and a sizeable proportion of patients will relapse after autoHSCT. By analogy to diffuse large B cell lymphoma, these patients may be treated with allogeneic (allo) HSCT with curative intent, but at the risk of significant morbidity and mortality. Given the advent of effective immunotherapy approaches for rel/ref PMBCL, it is important to better understand the toxicity and efficacy of alloHSCT in these patients, to which these new approaches could be an alternative. Therefore, we retrospectively studied the outcomes of alloHSCT in a multicenter cohort of 28 patients with rel/ref PMBCL who underwent transplantation at 4 centers. Most patients (79%) were sensitive to pretransplantation therapy and 86% received reduced-intensity conditioning. The overall progression-free survival (PFS), overall survival (OS), and cumulative incidences of nonrelapse mortality and relapse in the cohort at 5 years were 34%, 45%, 32%, and 33%, respectively. Outcomes were significantly better in patients with pretransplantation responsive disease (2-year PFS and OS of 50% and 58%, respectively) compared with refractory patients (2-year PFS and OS of 0%). In our multicenter retrospective study, alloHSCT produced durable remissions in a proportion of patients with treatment-sensitive disease before transplantation (5-year PFS of 44%) and should be considered in the treatment of patients with rel/ref PMBCL.


Subject(s)
Hematopoietic Stem Cell Transplantation , Lymphoma, B-Cell , Mediastinal Neoplasms , Adolescent , Adult , Allografts , Disease-Free Survival , Female , Humans , Lymphoma, B-Cell/mortality , Lymphoma, B-Cell/therapy , Male , Mediastinal Neoplasms/mortality , Mediastinal Neoplasms/therapy , Middle Aged , Remission Induction , Retrospective Studies , Survival Rate
5.
Haematologica ; 103(9): 1511-1517, 2018 09.
Article in English | MEDLINE | ID: mdl-29880613

ABSTRACT

Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated IGHV, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.


Subject(s)
Antineoplastic Agents/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Sulfonamides/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic/adverse effects , Disease Management , Drug Resistance, Neoplasm , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , Male , Middle Aged , Recurrence , Sulfonamides/administration & dosage , Sulfonamides/adverse effects , Survival Analysis , Treatment Outcome , Tumor Lysis Syndrome/etiology
6.
BMJ Case Rep ; 20102010 Nov 05.
Article in English | MEDLINE | ID: mdl-22791857

ABSTRACT

Inflammatory myopathies including polymyositis and dermatomyositis are autoimmune disorders presenting with characteristic muscle weakness. These diseases, especially dermatomyositis, have a well-known association with a wide variety of neoplasms including lung, breast, ovary and colon cancers. Here we report the case of a 58-year-old man who presented with a 3-week history of myositis and was simultaneously diagnosed with gastric cancer.


Subject(s)
Carcinoma/diagnosis , Paraneoplastic Syndromes/diagnosis , Polymyositis/etiology , Stomach Neoplasms/diagnosis , Carcinoma/pathology , Carcinoma/surgery , Electromyography , Gastroscopy , Humans , Lymphatic Metastasis/pathology , Male , Middle Aged , Paraneoplastic Syndromes/pathology , Paraneoplastic Syndromes/surgery , Polymyositis/diagnosis , Polymyositis/pathology , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Tomography, X-Ray Computed
7.
J Pediatr Hematol Oncol ; 28(12): 781-4, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17164645

ABSTRACT

PURPOSE: To study the rate of psychiatric disorder and suicidal behavior in children with thalassemia major. METHOD: One hundred ten subjects with thalassemia major were interviewed according to the K-SADS Farsi version by face-to-face interview. RESULT: The most common psychiatric disorders were major depressive disorder and separation anxiety disorder. The rate of oppositional defiant disorder, attention-deficit hyperactivity disorder, and bipolar mood disorder were 3.6%, 1.8%, and 0.9%, respectively. About 49% suffered from depressed mood and 62.7% suffered from irritability and anger. More than 43% of them had recurrent thought of death and 27.3% considered suicide in the last year. CONCLUSIONS: The rate of psychiatric disorders was very low than that in the prior studies and the most common was major depressive disorder. However, the rate of psychiatric symptoms was very common. The rate of suicidal behavior was not more than that in the general population.


Subject(s)
Bipolar Disorder/epidemiology , Depressive Disorder/epidemiology , Suicide , beta-Thalassemia/psychology , Adolescent , Bipolar Disorder/etiology , Bipolar Disorder/psychology , Child , Depressive Disorder/etiology , Depressive Disorder/psychology , Female , Humans , Interview, Psychological , Male , Suicide/psychology , beta-Thalassemia/complications , beta-Thalassemia/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...